The first patient could not move his legs at all. By the end of the first month, he was crossing the rehabilitation room on his own, without a harness holding him up and without a machine doing the work for him.
That is the claim a two-year-old company in Suzhou is making, and it is the reason investors just handed it nearly ¥100 million (≈ US$13.9 million / HK$108.7 million, approximate). The result, if it holds up in more patients, would mark a shift in how brain-computer interface (脑机接口) therapy is imagined: not a device that replaces a lost function, but a bridge that lets the body perform it again.
What a brain–spine interface actually does
Suzhou Ruiyi Xulian Medical Technology (苏州瑞意旭联医疗科技有限公司), founded in March 2024, calls its core product a brain–spine interface (脑脊接口), or BSI. Founder and chief executive Huang He (黄河) describes a system with two implanted ends.
One end sits over the motor cortex and reads the intention to move. The other sits on the spinal cord below the injury. Between them sits decoding software that converts a thought into a pattern of electrical stimulation, timed and placed to recruit the nerves that still control the legs.
The distinction matters. A brain-controlled exoskeleton carries the patient; switch it off and the ability disappears. A brain–spine interface is designed to make the patient's own muscles and spinal circuits do the walking, with sensory feedback travelling back up the intact pathways. The company is explicit that this is a "reconstruction" route rather than a "compensation" one. It is also explicit that the data so far comes from a very small number of people.
The two reported cases
The company says it has completed investigator-initiated trials (IIT) in two patients with complete spinal cord injury. Both were classified ASIA A, the most severe grade, with lesions at the T6 level and a WISCI walking score of zero before implantation.
According to the company's disclosure, the first patient showed movement in the hip, knee and ankle joints on the day after surgery. By the second week he could stand with the help of a standing frame. By the third week he was producing a continuous gait inside a suspension system. One month after the operation, rehabilitation staff assessed that he could walk more than 20 metres without external power or suspension support. Lower-limb motor and muscle scores also improved.
The second clinical line is stroke. In January 2026, the company reported the first implanted closed-loop brain-computer interface (脑机接口) procedure in Anhui, performed by the team of Professor Zhang Jianguo (张建国) at Beijing Tiantan Hospital. The patient was a 33-year-old man with right-sided hemiplegia after a brain haemorrhage. One week after surgery, the company says, upper-limb motor intention was decoded with an accuracy of no less than 95 percent, Fugl-Meyer upper-limb scores improved, and the patient could grasp blocks and lift a cup.
These are early human results, and they are company-reported. Neither has appeared as a peer-reviewed paper, and the follow-up periods are short.
Where the money goes
The round was a Pre-A+ financing led by Puhua Capital (普华资本) and Furong Investment (复容投资), with Songhe Capital (松禾资本) and Beigong Investment (北工投资) participating. Xingqiao Capital (星桥资本) acted as sole financial adviser. The company had closed a separate Pre-A round of a similar size in May 2026.
The proceeds are earmarked for three things: moving the brain–spine interface (脑脊接口) into a registered clinical trial; taking a modular implant platform into volume production; and extending the same hardware to language decoding, visual restoration and depression.
The modularity is the commercial argument. Instead of building one implant per condition, Ruiyi Xulian has broken its system into swappable blocks — electrode and sensor arrays, read modules, write modules, bidirectional modules, power and communications, and an AI compute module. Different combinations produce different products. The company argues this shortens development time when it moves from spinal cord injury to stroke to other targets.
There is also a cash-flow story, unusual in a sector known for long dry spells. The company says it holds four medical device registration certificates and expects revenue in the tens of millions of yuan (≈ US$1.4 million and up) in 2026, from non-implanted products such as portable electrical stimulation devices. It employs more than 80 people, including over 50 in research. Its own timetable puts type testing in 2027, a registration trial in 2027 and a Class III device certificate by the end of 2029. Those are plans, not approvals.
Why this is not the same story as an exoskeleton
A thought-to-cursor system can be evaluated in a lab session. A spinal bridge has to survive for years inside a moving body, control heat and power, and stay compatible with MRI scans. The company says its device uses wireless and wired dual power, a ceramic and sapphire package, and can be removed entirely if needed without damaging nervous tissue.
That engineering list is as important as the 20-metre walk, because it is the part that determines whether a demonstration becomes a product. The company says its electrodes and feed-through components have entered production and that its chip set has completed tape-out testing.
According to Li An, chief scientist at BrainNet (脑机网), the useful question after a first success is not whether a system works once, but whether it produces the same result in the next ten patients. That is the gap this round is meant to close.
Honest limitations
All clinical figures in this article come from Ruiyi Xulian's own disclosures, reported by investment and business media. I found no peer-reviewed publication, clinical trial registration record or independent assessment of the 20-metre result or the 95 percent decoding figure. "No less than 95 percent" is a company statement without a published protocol, sample definition or confidence interval.
The two IIT groups contain two patients each. That is enough to show a signal, not enough to establish safety or efficacy, and follow-up durations were not disclosed. The distinction between a harness-assisted step and unaided walking is clinically meaningful; the account here follows the company's wording.
Funding amounts are approximate conversions. The company's revenue expectation, product timeline and "first in China, second in the world" positioning are corporate claims, not audited results or regulatory findings. Nothing here is medical advice; patients should discuss any intervention with a qualified rehabilitation team.
What readers can do now
- If you follow brain-computer interface (脑机接口) news, separate the demonstration from the trial. Ask how many patients were studied, what their baseline was, and how long they were followed.
- If you are a clinician or researcher, watch for the registration trial. A Class III application, if it happens, will produce far more information than an investor announcement.
- If you are considering a device for yourself or a relative, ask who pays when the result is partial. Reconstruction routes require long rehabilitation; the cost question is rarely in the headline.
